Q-omics provides the consensus-scored ZNHIT6 profile across patient tissues and cancer cell-line models. ZNHIT6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZNHIT6 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, ZNHIT6 protein abundance shows 23,358 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, LUAD, and LSCC as cancer lineages where ZNHIT6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNHIT6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNHIT6 survival associations across molecular data types. ZNHIT6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNHIT6 RNA expression–survival associations across cancer types. High ZNHIT6 expression shows unfavorable associations in KIRP, LIHC, LGG, ACC and SARC, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZNHIT6 RNA expression.
This table summarizes ZNHIT6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNHIT6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNHIT6 shows lower tumor expression in THCA and higher tumor expression in LUAD, COAD, LIHC, BLCA and STAD. The LUAD box plot shows higher ZNHIT6 RNA expression in tumor versus normal tissue (log2 FC = +0.790, t-test p < 0.001).
This table shows molecular features associated with ZNHIT6 in patient tissues and cancer cell lines. In patient samples, ZNHIT6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNHIT6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
